Low-dose phase-shift protocol (Dylan-relevant: 0.3-0.5 mg, 5-7 hr before target bedtime):

• Most users report no acute "drug effect" at all. The mechanism is signaling, not sedation. You take 0.3 mg at 6-7 PM, you feel nothing notable, and you simply find yourself naturally sleepy at midnight after 1-2 weeks of consistent use plus behavioral anchors (light, schedule).
• No morning grogginess — physiological dose is cleared from plasma within hours of dosing time, well before wake-up.
• No vivid dreams at this dose typically — vivid-dream effects are dose-dependent and primarily a 3-10 mg phenomenon.
• Phase-advance becomes apparent over 1-3 weeks, not the first night. This is a chronobiology intervention, not a hypnotic.

Standard / high-dose sleep-onset protocol (3-10 mg at bedtime — NOT the recommended Dylan use):

• ~30-60 min onset of "drowsiness," more like "the room dimmed" than "I'm sedated"
• Sleep onset 7-15 min faster than baseline (small effect)
• Vivid, often bizarre dreams; some users find these enjoyable, some find them disturbing
• Morning effects highly variable: many users report fine mornings, but a meaningful subset reports grogginess, dampened mood, "fuzzy" feeling lasting hours into the day. This tracks with the high-dose plasma curve persisting into morning hours and occasional MT receptor desensitization.
• Mid-sleep awakening 4-5 hours after dose common, possibly due to rapid plasma decline triggering a wake-promoting paradoxical signal once exogenous melatonin clears.
• Heat dump / mild peripheral vasodilation early — contributes to the "slipping into sleep" feel since sleep onset is associated with core body temperature drop.

Honest variability: Maybe 10-15% of users get nothing perceptible from any dose; another 5-10% are "super-responders" who get strong sleep-onset effects from 0.3 mg. Polymorphisms in MTNR1A/MTNR1B receptors and CYP1A2 metabolism (melatonin's primary metabolic pathway) explain some of this variance.

• Tolerance buildup: minimal at physiological doses. No clinical tachyphylaxis has been demonstrated for low-dose chronic use through 12+ months of follow-up. Receptor desensitization is theoretically possible at supraphysiological doses with chronic plasma elevation but is not consistently observed in humans at standard supplement doses.
• Recommended cycle: not required. Can be used continuously through the chronotype-migration phase, then tapered when behavioral anchors hold the gain.
• Reset protocol if needed: If subjective effect fades, drop dose (lower doses often work better), or take 1-2 weeks off and resume. Most apparent "tolerance" is actually noise from inconsistent dosing time or competing zeitgebers (irregular wake time, weekend drift).
• Discontinuation: No taper required, no rebound insomnia. May see 1-2 days of sleep-timing wobble as the exogenous signal is removed; behavioral anchors carry the day after.

Synergistic with

• Magnesium glycinate (Dylan V4 — 400 mg elemental): Independent mechanisms (NMDA modulation + glycinergic relaxation vs MT1/MT2 signaling). Magnesium has its own modest sleep-onset evidence; combined effect is additive without conflict. Already in Dylan's stack.
• Magtein / magnesium L-threonate (Dylan V4): CNS-penetrating Mg form; theoretical synergy on NMDA/sleep architecture without melatonin-pathway conflict. Different mechanism, complementary timing.
• L-tryptophan (Dylan V5 planned, replaces glycine): Tryptophan feeds the upstream serotonin → melatonin biosynthesis pathway. Tryptophan at bedtime + low-dose melatonin at early evening = layered chronotype + sleep-onset stack, both mechanism-aligned. The combination is rational; do NOT take both at the same time (substrate-flooding without a phase-shift signal is wasted; dosing them at different times preserves both signals).
• Apigenin (Dylan V5 planned, 50 mg): Mild GABA-A PAM at low doses, plus aromatase inhibition (irrelevant here). Different mechanism; safe co-admin. Apigenin near bedtime + low-dose melatonin in early evening is fine.
• Morning bright light (Uvex glasses + outdoor cardio + 10,000-lux box): The other zeitgeber. Morning light advances the clock from the wake side; low-dose evening melatonin advances it from the sleep side. Combined zeitgeber effect is the recommended chronotherapy across all DSWPD literature.
• Behavioral CBT-I / sleep restriction: Not a stack but a co-intervention. Strongly compatible.

Avoid stacking with

• High-dose 5-HTP or tryptophan at the same time as melatonin: substrate-flooding without coordinated phase signal; no benefit, theoretical risk of central serotonin excess at very high combined doses. Different timing is fine.
• Sedative drugs without prescriber sign-off (benzos, Z-drugs, phenibut, GHB, opioids, gabapentinoids, alcohol): additive sedation. Melatonin + a real hypnotic is rarely necessary; the layering is usually wrong (treating circadian + sleep with two different mechanisms makes more sense than two redundant hypnotics).
• Fluvoxamine (CYP1A2 inhibitor): substantially elevates melatonin plasma levels, prolongs duration. Dose adjustment or avoidance needed if both are required. Same caution applies (smaller magnitude) to ciprofloxacin and other CYP1A2 inhibitors.
• Warfarin and other coumarin anticoagulants: Possible enhancement of anticoagulant effect (unclear mechanism, possibly via vitamin K modulation or platelet effects). Watch INR if combined.
• SSRIs: Theoretical concern about additive serotonergic loading via the tryptophan → melatonin pathway and central 5-HT effects, though clinically the interaction signal is weak. Not a hard contraindication; flag for awareness if Dylan ever adds an SSRI.
• Bright light exposure at melatonin dose time: Defeats the signal — light suppresses MT2 receptor signaling (and endogenous pineal output). Take the dose in dim light, sit through the dose period in dim light.

Neutral / safe co-administration

• All V4 stack items (DHA, citicoline, NAC, PS, curcumin, rhodiola, theanine, D3+K2, beta-alanine, vitamin C, glycine): no PK or PD conflicts, all safe co-admin.
• Modafinil 100 mg AM (Dylan V5): mechanism (orexin/histamine wake) and timing (morning) entirely orthogonal; no conflict. Modafinil's wake-promoting effect can extend sleep latency if dosed late, but properly dosed (before noon) it does not interfere with evening melatonin's phase-shift signal.
• Bromantane / Adamax / Semax / ALCAR (Dylan V5): All AM dosing; no overlap.
• Caffeine (Dylan V4): caffeine cutoff should be ≥10 hr pre-bed regardless. Both substances are CYP1A2 substrates but do not meaningfully interact at supplement doses.
• Creatine, beta-alanine: no interaction.

CYP enzymes: Melatonin is primarily metabolized by CYP1A2 (~90%) to 6-hydroxymelatonin, then conjugated and excreted as urinary 6-sulfatoxymelatonin. Minor pathways: CYP2C19, CYP2C9. Melatonin does not significantly induce or inhibit CYPs at standard doses — interactions are one-way (other drugs affect melatonin, not vice versa).

Practical for Dylan: No current V4/V5 medications meaningfully interact at the 0.3-0.5 mg dose. Modafinil is a mild CYP1A2 inducer at high chronic doses — at 100 mg/day this is unlikely to change melatonin exposure meaningfully, but if Dylan finds his sleep timing harder to lock in after V5 modafinil onboarding, increasing melatonin dose modestly (to 0.5 mg) would compensate. Caffeine cutoff timing matters more than the metabolic interaction.

MTNR1A / MTNR1B receptor SNPs:

• MTNR1B rs10830963 (G allele): Associated with delayed melatonin offset, fasting glucose effects, and Type 2 diabetes risk. Carriers may have prolonged morning melatonin and later natural wake time. Clinically relevant for Dylan's chronotype phenotype if carrier — would partially explain late chronotype as genetic, not behavioral. Reported on 23andMe.
• MTNR1A SNPs (rs2119882, rs6553010): Less well-characterized; some links to seasonal affective disorder and chronotype.

CYP1A2 polymorphisms (drives metabolic clearance of melatonin):

• CYP1A2*1F (rs762551): high-inducibility allele; *1F homozygotes (esp. with smoking) clear melatonin faster → may need higher dose for similar plasma exposure. *1F is the dominant Caucasian variant (~60% allele frequency).
• CYP1A2*1C (rs2069514): reduced-activity allele; higher melatonin exposure at standard doses.

PER3 VNTR / CRY1 / CLOCK gene variants:

• PER3 4/4 vs 5/5 VNTR: 5/5 carriers tend toward morning chronotype; 4/4 carriers tend toward evening. Not melatonin-PK relevant but useful for understanding Dylan's late chronotype phenotype.
• CRY1 c.1657+3A>C variant: Associated with familial DSWPD. If Dylan carries, his chronotype is genetically reinforced and behavioral migration may be limited; melatonin and bright light remain the most effective interventions.
• 23andMe coverage for these: rs10830963 (MTNR1B) is well-covered; PER3 VNTR is less reliably covered on standard arrays — interpretation services like Promethease/SelfDecode help fill gaps.

Practical action for Dylan after 23andMe (June 2026):

• Pull MTNR1B rs10830963: G allele carrier → late chronotype is genetically biased, melatonin response should be intact, expect modest behavioral migration ceiling (chronotype may settle at 12:30-1 AM rather than 10 PM)
• Pull PER3 VNTR if available: 4/4 confirms evening chronotype genetic baseline
• Pull CYP1A2 rs762551: *1F homozygous → may benefit from 0.5 mg over 0.3 mg (faster clearance)

No CPIC guideline for melatonin dosing exists; pharmacogenomic data is suggestive, not prescriptive.

Practical sourcing for Dylan (US):

• Recommended: Life Extension Melatonin 300 mcg from iHerb (already a vendor in his V4 cart). $5-10 buys ~6 months supply. Clean dose, no gummy mislabeling risk.
• Alternative: NOW Foods 1 mg, halved or quartered with pill cutter (Dylan already has one in V4 Amazon list).
• Stay off Amazon for melatonin specifically — the gummy / pill quality control is genuinely worse than for most supplements, and the dose ranges are wrong for his use case.

Estimated cost for Dylan: ~$2-3/month amortized. Negligible relative to V4/V5 stack budget.

Baseline (before starting)

• Sleep diary 14 days: sleep onset time, wake time, total sleep time, mid-sleep awakenings, morning alertness 1-10. Dylan should be running this already as part of chronotype migration tracking.
• MEQ (Horne-Östberg Morningness-Eveningness Questionnaire) — single-shot chronotype assessment, free online
• MCTQ (Munich ChronoType Questionnaire) mid-sleep on free days — better than MEQ for actual chronotype phenotype
• Wearable sleep tracking — Colmi R06 ring data Dylan already has provides imperfect but useful baseline
• Optional: salivary melatonin ELISA / DLMO — gold-standard chronotype marker; rarely run outside research, requires evening saliva sampling in dim light. Not needed for routine clinical use.
• Optional: urinary 6-sulfatoxymelatonin — overnight collection, integrates total melatonin output. Available via specialty labs.
• Bloodwork (June 2026 panel): No specific melatonin labs needed; standard CMP fine. Low-dose melatonin doesn't require lab monitoring.

During use

• Sleep diary continuous through first 6 weeks of phase-advance protocol — track sleep onset advance vs target weekly
• Morning alertness 1-10 every morning — most important biomarker for Dylan-archetype: brain-priority means morning fog is disqualifying even if sleep timing improves
• Dream content / parasomnia log — note vivid dreams, mid-sleep awakenings; if disturbing, drop dose
• Weekend drift tracking — chronotype migration only locks if weekend wake time stays within ±60 min of weekday wake time
• Wearable sleep stage data — Colmi R06 will capture sleep timing, fragmentation; less reliable for sleep stages but useful trend

Post-discontinuation

• Sleep diary for 2-4 weeks post-stop — assess whether circadian gain held by behavioral anchors or regressed. If regression, consider continuing low-dose melatonin during high-stress / travel periods PRN.